Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc....
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.
Target Price
The average target price of JANX is 60 and suggests 348% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell